How do you counsel patients with metastatic TNBC on their various treatment options after progression on first line regimens?

The choice of a regimen would typically weigh:

• Expected efficacy. It is important to acknowledge that outside of the 1st and 3rd line settings, there may not be much data to guide the selection of one regimen over another.
• Expected toxicity. This includes side effects such as neuropathy, etc but wo...

Discuss efficacy versus toxicity. If rapid progression on first-line chemotherapy, would be less likely to use regular chemotherapy.

As per NCCN guidelines, there are a number of treatment options in the 2nd line and beyond mTNBC setting. The choice is based on the efficacy, adverse effect profile, and patient preference of oral vs intravenous medication.